
AEON Biopharma
Developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions.
Market cap
$9.0m
Enterprise value
$17m
Share price
$0.78 AEON
Authorizing premium user...
Developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions.